Aspartate aminotransferase to platelet ratio index – a reliable predictor of therapeutic efficacy and improvement of Ishak score in chronic hepatitis B patients treated with nucleoside analogues

References

• Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Inter 2012;6:531–61.
   PubMed Web of Science ®Google Scholar
• Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011;53:885–94.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85.
   PubMed Web of Science ®Google Scholar
• Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40
   PubMed Web of Science ®Google Scholar
• Kim SU, Park JY, Kim DY, Ahn SH, Choi EH, Seok JY, Lee JM, Park YN, Chon CY, Han KH. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int 2010;4:673–80.
   PubMed Web of Science ®Google Scholar
• Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300–14.
   PubMed Web of Science ®Google Scholar
• Lesmana CR, Salim S, Hasan I, Sulaiman AS, Gani RA, Pakasi LS, Lesmana LA, Krisnuhoni E, Budihusodo U. Diagnostic accuracy of transient elastography (FibroScan) versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B: the role in primary care setting. J Clin Pathol 2011;64:916–20.
   PubMed Web of Science ®Google Scholar
• Erdogan S, Dogan HO, Sezer S, Uysal S, Ozhamam E, Kayacetin S, Koca Y. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest 2013;73:300–8.
   PubMed Web of Science ®Google Scholar
• Ucar F, Sezer S, Ginis Z, Ozturk G, Albayrak A, Basar O, Ekiz F, Coban S, Yuksel O, Armutcu F, Akbal E. APRI, the FIB-4 score, and Forn’s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2013;25:1076–81.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang JY, Lu Y. Serum fibrosis markers in diagnosing liver fibrosis. Zhonghua Nei Ke Za Zhi 2006;45:475–7.
   PubMedGoogle Scholar
• Messina MF, Squadrito G, Valenzise M, Maimone S, Iannelli S, Arrigo T, Cacciola I, Civa R, D’agata V, Raimondo G, De Luca F. Fibroscan: a new noninvasive method for evaluation of liver dysfunction in Turner syndrome. Eur J Clin Invest 2011;41:183–8.
   PubMed Web of Science ®Google Scholar
• Stefanescu H, Grigorescu M, Lupsor M, Procopet B, Maniu A, Badea R. Spleen stiffness measurement using Fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients. J Gastroenterol Hepatol 2011;26:164–70.
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng J, Hou J. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356–68.
   PubMed Web of Science ®Google Scholar
• Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf) 2013;1:19–26.
   PubMedGoogle Scholar
• Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, Mak B, Oo AM, Lim SG. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006;26:666–72.
   PubMed Web of Science ®Google Scholar
• Liu HB, Zhou JP, Zhang Y, Lv XH, Wang W. Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B. Clin Chim Acta 2011;412:33–7.
   PubMed Web of Science ®Google Scholar
• Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat 2013;20:e3–10.
   PubMed Web of Science ®Google Scholar
• Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 2011;11:103–7.
   PubMed Web of Science ®Google Scholar
• Gümüsay O, Ozenirler S, Atak A, Sönmez C, Ozkan S, Tuncel AF, Yılmaz G, Akyol G. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2013;43:228–37.
   PubMed Web of Science ®Google Scholar
• Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, Jun SY, Park CK. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008;40:267–74.
   PubMedGoogle Scholar
• Ohkoshi S, Yamagiwa S, Yano M, Takahashi H, Aoki YH, Matsuda Y, Aoyagi Y. Very-low-dose pegylated interferonα2a plus ribavirin therapy for advanced liver cirrhosis type C: a possible therapeutic alternative without splenic intervention. Case Rep Gastroenterol 2010;4:261–6.
   PubMedGoogle Scholar
• Diseases Chinese Society of Hepatology Association Chinese Medical. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Hepatol 2011;19:13–24.
   PubMedGoogle Scholar
• Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 2014;59:1283–92.
   PubMed Web of Science ®Google Scholar
• Wang GQ. Multicenter, randomized, open-label, active-control trial investigating the efficacy of Y-branched pegalyted recombinant human interferonα2b injection in the treatment of chronic hepatitis B. Peking University First Hospital, 2010.
   Google Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, Macsween RN, Phillips MG, Portmann B, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Lemeshow S. Applied logistic regression, 2nd edn. New York: John Wiley & Sons; 2000.
   Google Scholar
• World Health Organization (WHO). Guideline for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva, Switzerland: WHO Press, 2015.
   Google Scholar
• Shoaei SD, Sali S, Karamipour M, Riahi E. Non-invasive histologic markers of liver disease in patients with chronic hepatitis B. Hepat Mon 2014;14:e14228
   PubMed Web of Science ®Google Scholar
• Zhijian Y, Hui L, Weiming Y, Zhanzhou L, Zhong C, Jinxin Z, Hongyan W, Xiangbin D, Weizhi Y, Duoyun L, Xiaojun L, Qiwen D. Role of the aspartate transaminase and platelet ratio index in assessing hepatic fibrosis and liver inflammation in adolescent patients with HBeAg-positive chronic hepatitis B. Gastroenterol Res Pract 2015;32:83–6.
   Google Scholar
• Shaheen AAM, Myers RP. Diagnostic accuracy of the Aspartate aminotransferase-to-Platelet Ratio Index for the prediction of Hepatitis C-related fibrosis: a systematic review. Hepatology 2007;46:912–21.
   PubMed Web of Science ®Google Scholar
• Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt M, Lu M for the Chronic Hepatitis Cohort Study (CHeCS) Investigators. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat 2014;21:930–7.
   PubMed Web of Science ®Google Scholar
• Celikbilek M, Dogan S, Gursoy S, Zararsiz G, Yurci A, Ozbakir O, Guven K, Yucesoy M. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol 2013;5:439–45.
   PubMedGoogle Scholar
• Teshale E, Lu M, Rupp LB, Homberg SD, Moorman AC, Spradling P, Vijayadeva V, Boscarino JA, Schmidt M, Gordon SC for the CheCS Investigators. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat 2014;21:917–20.A.
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong CF, Yang G, Liu J, Yao S, Li HY, Yuan J, Li S, Le X, Lin Y, Zeng W, Lin H, Zhang X, Chen X. Optimal linear combination of ARFI, transient elastography and APRI for the assessment of fibrosis in chronic hepatitis B. Liver Int 2015;35:816–25.
   PubMed Web of Science ®Google Scholar
• Koksal AR, Alkim H, Boga S, Ergun M, Bayram M, Ozguven BY, Alkim C. Effect of entecavir and tenofovir treatment on noninvasive fibrosis scores: which one is better? Am J Ther 2015 Feb 2; [Epub ahead of print] PubMed PMID: 25650531.
   Google Scholar
• Shin SK, Kim JH, Park H, Kwon OS, Lee HJ, Yeon JE, Byun KS, Suh SJ, Yim HJ, Kim YS, Kim JH. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. J Gastroenterol Hepatol 2015; doi: 10.1111/jgh.13020. [Epub ahead of print] PubMed PMID: 26095700.
   Web of Science ®Google Scholar
• Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen H, HBV 99-01 Study Group. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007;46:388–94.
   PubMed Web of Science ®Google Scholar